• English
  • 简体中文
Login Register
Current Location: Home > Feedback Help Print

【结 构 式】

【药物名称】Linagliptin, BI-1356, BI-1356-BS, Ondero

【化学名称】8-[3(R)-Aminopiperidin-1-yl]-7-(2-butynyl)-3-methyl-1-(4-methylquinazolin-2-ylmethyl)xanthine

【CA登记号】668270-12-0

【 分 子 式 】C25H28N8O2

【 分 子 量 】472.5422

【开发单位】Boehringer Ingelheim GmbH (DE).

【药理作用】dipeptidyl-peptidase IV inhibitor, Antidiabetic Agent

合成路线1

BI-1356 can be synthesized as follows. Cyclization of 2-aminoacetophenone (I) with chloroacetonitrile (II) in the presence of HCl in dioxane gives 2-(chloromethyl)-4-methylquinazoline (III) (1), which can also be prepared by reaction of 2-(chloromethyl)-4-methylquinazoline-3-oxide (IV) with PCl3 in refluxing chloroform (2). Coupling of the quinazoline derivative (III) with 3-methyl-7-(2-butyn-1-yl)-8-bromoxanthine (V) –prepared by treatment of 8-bromo-3-methylxanthine (VI) with butyn-2-yl bromide (VII) in the presence of TEA or DIEA in DMF (3)–, in the presence of Na2CO3 or K2CO3 provides 1-(4-methylquinazolin-2-ylmethyl)-3-methyl-7-(2-butyn-1-yl)-8-bromoxanthine (VIII). Condensation of bromoxanthine (VIII) with (R)-3-(phthalimido)piperidine D-tartrate (IX) affords the adduct (X), which is deprotected by heating with 2-aminoethanol in either toluene at 85 ºC or in THF at 65 ºC (1). Scheme 1.
The title compound can also be prepared by coupling of the bromoxanthine (VIII) with 3(R)-(tert-butoxycarbonylamino)piperidine (XI) by means of K2CO3 in DMF to give the N-protected piperidine derivative (XII), which is deprotected with TFA in CH2Cl2 (2, 3). Scheme 1.

1 Pfrengle, W., Pachur, T., Nicola, T., Duran, A. (Boehringer Ingelheim Corp.). Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)xanthines. US 2006142310.
2 Himmelsbach, F., Langkopf, E., Eckhardt, M., Mark, M. Maier, R., Lotz, R.R.H., Tadayyon, M. (Boehringer Ingelheim Corp.). 8-[3-Amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions. US 2004097510.
3 Eckhardt, M., Langkopf, E., Mark, M. et al. 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007, 50(26): 6450-3.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 65634 2-Aminoacetophenone;2'-Aminoacetophenone; o-Aminoacetophenone; 1-(2-Aminophenyl)ethanone 551-93-9 C8H9NO 详情 详情
(II) 14443 2-chloroacetonitrile; chloroacetonitrile 107-14-2 C2H2ClN 详情 详情
(III) 65635 2-(Chloromethyl)-4-methylquinazoline 109113-72-6 C10H9ClN2 详情 详情
(IV) 65636     C10H9ClN2O 详情 详情
(V) 65637     C10H11BrN4O2 详情 详情
(VI) 65638     C6H7BrN4O2 详情 详情
(VII) 29428 1-bromo-2-butyne 3355-28-0 C4H5Br 详情 详情
(VIII) 65639     C20H19BrN6O2 详情 详情
(IX) 65640     C14H14N2O2.C4H4O6 详情 详情
(X) 65641     C33H32N8O4 详情 详情
(XI) 65642 (R)-3-(Boc-Amino)piperidine; (R)-(+)-3-tert-Butoxycarbonylaminopiperidine 309956-78-3 C10H20N2O2 详情 详情
(XII) 65643     C30H38N8O4 详情 详情
Extended Information